Study of the Safety and Pharmacokinetics of BGB-283 in Patients With Solid Tumors
NCT02610361
·
clinicaltrials.gov ↗
PHASE1
Phase
COMPLETED
Status
131
Enrollment
INDUSTRY
Sponsor class
Conditions
Solid Tumors
Interventions
DRUG:
BGB-283
Sponsor
BeiGene